Paolo Corradini

51PUBLICATIONS
386CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Jul 24, 2026
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

|May 05, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

|Oct 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Martin Hutchings, Anna Sureda, Francesc Bosch

|Aug 05, 2025
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.

Anna Dodero, Giusy Ceparano, Beatrice Casadei

|Jul 22, 2025
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.

Angelica Barone, Chiara De Philippis, Federico Stella

Pageof 9

Frequent Collaborators

11 joint publications

Pierluigi Zinzani

10 joint publications

Annalisa Chiappella

7 joint publications

Francesco Passamonti

7 joint publications

Federico Stella